Overview

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa for less than 2 years.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Ropinirole